Infections in Kidney Transplant Recipients



Kidney transplant is the most common type of organ transplantation worldwide. In preparation for transplantation, appropriate infectious disease testing of the donor and recipient is required. In the posttransplant period, infections within the first 1 month generally include urinary tract infection, pneumonia, and wound infections. There is increasing prevalence of multidrug-resistant bacterial infections after kidney transplantation. Syndromes of specific interest in kidney transplant recipients include asymptomatic bacteriuria, recurrent UTI, and candiduria. Kidney transplant recipients are predisposed to several opportunistic viral infections including cytomegalovirus, BK virus, adenovirus, and parvovirus. There are also increasing number of HIV-positive recipients undergoing kidney transplant and there needs to be special attention to drug interactions in this population. Finally, infection prevention for kidney transplant recipients includes chemoprophylaxis and vaccinations.


Urinary tract infection Postoperative complications Viral infection Candiduria Vaccination 


  1. 1.
  2. 2.
    Veroux M, Giuffrida G, Corona D, Gagliano M, Scriffignano V, Vizcarra D, et al. Infective complications in renal allograft recipients: epidemiology and outcome. Transplant Proc. 2008;40(6):1873–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Charfeddine K, Zaghden S, Kharrat M, Kamoun K, Jarraya F, Hachicha J. Infectious complications in kidney transplant recipients: a single-center experience. Transplant Proc. 2005;37(6):2823–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Al-Hasan MN, Razonable RR, Eckel-Passow JE, Baddour LM. Incidence rate and outcome of Gram-negative bloodstream infection in solid organ transplant recipients. Am J Transplant. 2009;9(4):835–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Alangaden GJ, Thyagarajan R, Gruber SA, Morawski K, Garnick J, El-Amm JM, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transpl. 2006;20(4):401–9.CrossRefGoogle Scholar
  6. 6.
    Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338(24):1741–51.PubMedCrossRefGoogle Scholar
  7. 7.
    Bige N, Zafrani L, Lambert J, Peraldi MN, Snanoudj R, Reuter D, et al. Severe infections requiring intensive care unit admission in kidney transplant recipients: impact on graft outcome. Transpl Infect Dis. 2014;16(4):588–96.PubMedCrossRefGoogle Scholar
  8. 8.
    Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601–14.PubMedCrossRefGoogle Scholar
  9. 9.
    Fischer SA, Lu K, Practice ASTIDCo. Screening of donor and recipient in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:9–21.Google Scholar
  10. 10.
    Waheed S, Sakr A, Chheda ND, Lucas GM, Estrella M, Fine DM, et al. Outcomes of renal transplantation in HIV-1 associated nephropathy. PLoS One. 2015;10(6):e0129702.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis. 2001;38(5):919–34.PubMedCrossRefGoogle Scholar
  12. 12.
    Guidelines for counseling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Centers for Disease Control and Prevention and the U.S.P.H.S. Working Group. Ann Internal Med. 1993;118(6):448–54.Google Scholar
  13. 13.
    Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol. 2015;12(5):284–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Sester M, Sester U, Clauer P, Heine G, Mack U, Moll T, et al. Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. Kidney Int. 2004;65(5):1826–34.PubMedCrossRefGoogle Scholar
  15. 15.
    Winthrop KL, Nyendak M, Calvet H, Oh P, Lo M, Swarbrick G, et al. Interferon-gamma release assays for diagnosing mycobacterium tuberculosis infection in renal dialysis patients. Clin J Am Soc Nephrol. 2008;3(5):1357–63.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Lee SS, Chou KJ, Su IJ, Chen YS, Fang HC, Huang TS, et al. High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test. Infection. 2009;37(2):96–102.PubMedCrossRefGoogle Scholar
  17. 17.
    Fang HC, Chou KJ, Chen CL, Lee PT, Chiou YH, Hung SY, et al. Tuberculin skin test and anergy in dialysis patients of a tuberculosis-endemic area. Nephron. 2002;91(4):682–7.PubMedCrossRefGoogle Scholar
  18. 18.
    American Thoracic S, Centers for Disease C, Prevention, Infectious Diseases Society of A. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005;172(9):1169–227.CrossRefGoogle Scholar
  19. 19.
    Danziger-Isakov L, Kumar D, Practice ASTIDCo. Vaccination in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:311–7.Google Scholar
  20. 20.
    Schweitzer EJ, Perencevich EN, Philosophe B, Bartlett ST. Estimated benefits of transplantation of kidneys from donors at increased risk for HIV or hepatitis C infection. Am J Transplant. 2007;7(6):1515–25.PubMedCrossRefGoogle Scholar
  21. 21.
    group Cirdw. Guidance on the use of increased infectious risk donors for organ transplantation. Transplantation. 2014;98(4):365–9.Google Scholar
  22. 22.
    Viral hepatitis guidelines in hemodialysis and transplantation. Am J Transplant. 2004;4 Suppl 10:72–82.Google Scholar
  23. 23.
    Huprikar S, Danziger-Isakov L, Ahn J, Naugler S, Blumberg E, Avery RK, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015;15(5):1162–72.PubMedCrossRefGoogle Scholar
  24. 24.
    Schmidt T, Schub D, Wolf M, Dirks J, Ritter M, Leyking S, et al. Comparative analysis of assays for detection of cell-mediated immunity toward cytomegalovirus and M. tuberculosis in samples from deceased organ donors. Am J Transplant. 2014;14(9):2159–67.PubMedCrossRefGoogle Scholar
  25. 25.
    Freeman RB, Giatras I, Falagas ME, Supran S, O’Connor K, Bradley J, et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation. 1999;68(8):1107–11.PubMedCrossRefGoogle Scholar
  26. 26.
    Palacios G, Druce J, Du L, Tran T, Birch C, Briese T, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med. 2008;358(10):991–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Fischer SA, Graham MB, Kuehnert MJ, Kotton CN, Srinivasan A, Marty FM, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med. 2006;354(21):2235–49.PubMedCrossRefGoogle Scholar
  28. 28.
    Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, Sutker WL, Ksiazek TG, et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med. 2005;352(11):1103–11.PubMedCrossRefGoogle Scholar
  29. 29.
    Vora NM, Basavaraju SV, Feldman KA, Paddock CD, Orciari L, Gitterman S, et al. Raccoon rabies virus variant transmission through solid organ transplantation. JAMA. 2013;310(4):398–407.PubMedCrossRefGoogle Scholar
  30. 30.
    Maier T, Schwarting A, Mauer D, Ross RS, Martens A, Kliem V, et al. Management and outcomes after multiple corneal and solid organ transplantations from a donor infected with rabies virus. Clin Infect Dis. 2010;50(8):1112–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Basavaraju SV, Kuehnert MJ, Zaki SR, Sejvar JJ. Encephalitis caused by pathogens transmitted through organ transplants, United States, 2002-2013. Emerg Infect Dis. 2014;20(9):1443–51.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Bemelman F, De Blok K, De Vries P, Surachno S, Ten Berge I. Falciparum malaria transmitted by a thick blood smear negative kidney donor. Scand J Infect Dis. 2004;36(10):769–71.PubMedCrossRefGoogle Scholar
  33. 33.
    Chiche L, Lesage A, Duhamel C, Salame E, Malet M, Samba D, et al. Posttransplant malaria: first case of transmission of Plasmodium falciparum from a white multiorgan donor to four recipients. Transplantation. 2003;75(1):166–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Cortes NJ, Afzali B, MacLean D, Goldsmith DJ, O’Sullivan H, Bingham J, et al. Transmission of syphilis by solid organ transplantation. Am J Transplant. 2006;6(10):2497–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Gibel LJ, Sterling W, Hoy W, Harford A. Is serological evidence of infection with syphilis a contraindication to kidney donation? Case report and review of the literature. J Urol. 1987;138(5):1226–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Morris MI, Daly JS, Blumberg E, Kumar D, Sester M, Schluger N, et al. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report. Am J Transplant. 2012;12(9):2288–300.PubMedCrossRefGoogle Scholar
  37. 37.
    Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27(5):1266–77.PubMedCrossRefGoogle Scholar
  38. 38.
    Levi ME, Kumar D, Green M, Ison MG, Kaul D, Michaels MG, et al. Considerations for screening live kidney donors for endemic infections: a viewpoint on the UNOS policy. Am J Transplant. 2014;14(5):1003–11.PubMedCrossRefGoogle Scholar
  39. 39.
    Humar A, Matas AJ. Surgical complications after kidney transplantation. Semin Dial. 2005;18(6):505–10.PubMedCrossRefGoogle Scholar
  40. 40.
    Hernandez D, Rufino M, Armas S, Gonzalez A, Gutierrez P, Barbero P, et al. Retrospective analysis of surgical complications following cadaveric kidney transplantation in the modern transplant era. Nephrol Dial Transplant. 2006;21(10):2908–15.PubMedCrossRefGoogle Scholar
  41. 41.
    Humar A, Ramcharan T, Denny R, Gillingham KJ, Payne WD, Matas AJ. Are wound complications after a kidney transplant more common with modern immunosuppression? Transplantation. 2001;72(12):1920–3.PubMedCrossRefGoogle Scholar
  42. 42.
    Munoz P. Management of urinary tract infections and lymphocele in renal transplant recipients. Clin Infect Dis. 2001;33 Suppl 1:S53–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Bischof G, Rockenschaub S, Berlakovich G, Langle F, Muhlbacher F, Fugger R, et al. Management of lymphoceles after kidney transplantation. Transplant Int. 1998;11(4):277–80.CrossRefGoogle Scholar
  44. 44.
    Rao PS, Ravindran A, Elsamaloty H, Modi KS. Emphysematous urinoma in a renal transplant patient. Am J Kidney Dis. 2001;38(5):E29.PubMedCrossRefGoogle Scholar
  45. 45.
    de Souza RM, Olsburgh J. Urinary tract infection in the renal transplant patient. Nat Clin Pract Nephrol. 2008;4(5):252–64.PubMedCrossRefGoogle Scholar
  46. 46.
    Schmaldienst S, Dittrich E, Horl WH. Urinary tract infections after renal transplantation. Curr Opin Urol. 2002;12(2):125–30.PubMedCrossRefGoogle Scholar
  47. 47.
    Chuang P, Parikh CR, Langone A. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin Transpl. 2005;19(2):230–5.CrossRefGoogle Scholar
  48. 48.
    Parasuraman R, Julian K, Practice ASTIDCo. Urinary tract infections in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:327–36.Google Scholar
  49. 49.
    Wilson CH, Bhatti AA, Rix DA, Manas DM. Routine intraoperative ureteric stenting for kidney transplant recipients. Cochrane Database Syst Rev. 2005;4:CD004925.Google Scholar
  50. 50.
    Fujita S, Watanabe J, Reed AI, Hemming AW, Solis D, Netzel TC, et al. Case of emphysematous pyelonephritis in a renal allograft. Clin Transpl. 2005;19(4):559–62.CrossRefGoogle Scholar
  51. 51.
    Boltan LE, Randall H, Barri YM. Iatrogenic emphysematous pyelonephritis in a renal transplant patient. Transpl Infect Dis. 2008;10(6):409–12.PubMedCrossRefGoogle Scholar
  52. 52.
    Chuang YW, Chen CH, Cheng CH, Hung SW, Yu TM, Wu MJ, et al. Severe emphysematous pyelonephritis in a renal allograft: successful treatment with percutaneous drainage and antibiotics. Clin Nephrol. 2007;68(1):42–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Lee JR, Bang H, Dadhania D, Hartono C, Aull MJ, Satlin M, et al. Independent risk factors for urinary tract infection and for subsequent bacteremia or acute cellular rejection: a single-center report of 1166 kidney allograft recipients. Transplantation. 2013;96(8):732–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Abbott KC, Swanson SJ, Richter ER, Bohen EM, Agodoa LY, Peters TG, et al. Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis. 2004;44(2):353–62.PubMedCrossRefGoogle Scholar
  55. 55.
    Smith SD, Wheeler MA, Lorber MI, Weiss RM. Temporal changes of cytokines and nitric oxide products in urine from renal transplant patients. Kidney Int. 2000;58(2):829–37.PubMedCrossRefGoogle Scholar
  56. 56.
    Kamath NS, John GT, Neelakantan N, Kirubakaran MG, Jacob CK. Acute graft pyelonephritis following renal transplantation. Transpl Infect Dis. 2006;8(3):140–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Giral M, Pascuariello G, Karam G, Hourmant M, Cantarovich D, Dantal J, et al. Acute graft pyelonephritis and long-term kidney allograft outcome. Kidney Int. 2002;61(5):1880–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Pelle G, Vimont S, Levy PP, Hertig A, Ouali N, Chassin C, et al. Acute pyelonephritis represents a risk factor impairing long-term kidney graft function. Am J Transplant. 2007;7(4):899–907.PubMedCrossRefGoogle Scholar
  59. 59.
    Ariza-Heredia EJ, Beam EN, Lesnick TG, Cosio FG, Kremers WK, Razonable RR. Impact of urinary tract infection on allograft function after kidney transplantation. Clin Transpl. 2014;28(6):683–90.CrossRefGoogle Scholar
  60. 60.
    Rice JC, Peng T, Kuo YF, Pendyala S, Simmons L, Boughton J, et al. Renal allograft injury is associated with urinary tract infection caused by Escherichia coli bearing adherence factors. Am J Transplant. 2006;6(10):2375–83.PubMedCrossRefGoogle Scholar
  61. 61.
    Khosroshahi HT, Mogaddam AN, Shoja MM. Efficacy of high-dose trimethoprim-sulfamethoxazol prophylaxis on early urinary tract infection after renal transplantation. Transplant Proc. 2006;38(7):2062–4.PubMedCrossRefGoogle Scholar
  62. 62.
    Maki DG, Fox BC, Kuntz J, Sollinger HW, Belzer FO. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim-sulfamethoxazole, interaction with cyclosporine. J Lab Clin Med. 1992;119(1):11–24.PubMedGoogle Scholar
  63. 63.
    Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med. 1990;89(3):255–74.PubMedCrossRefGoogle Scholar
  64. 64.
    Valera B, Gentil MA, Cabello V, Fijo J, Cordero E, Cisneros JM. Epidemiology of urinary infections in renal transplant recipients. Transplant Proc. 2006;38(8):2414–5.PubMedCrossRefGoogle Scholar
  65. 65.
    Moyses Neto M, Costa RS, Reis MA, Ferraz AS, Saber LT, Batista ME, et al. Use of ciprofloxacin as a prophylactic agent in urinary tract infections in renal transplant recipients. Clin Transpl. 1997;11(5 Pt 1):446–52.Google Scholar
  66. 66.
    Wojciechowski D, Chandran S. Effect of ciprofloxacin combined with sulfamethoxazole-trimethoprim prophylaxis on the incidence of urinary tract infections after kidney transplantation. Transplantation. 2013;96(4):400–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Freire MP, Abdala E, Moura ML, de Paula FJ, Spadao F, Caiaffa-Filho HH, et al. Risk factors and outcome of infections with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in kidney transplant recipients. Infection. 2015;43(3):315–23.PubMedCrossRefGoogle Scholar
  68. 68.
    Bergamasco MD, Barroso Barbosa M, de Oliveira GD, Cipullo R, Moreira JC, Baia C, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis. 2012;14(2):198–205.PubMedCrossRefGoogle Scholar
  69. 69.
    Reid GE, Grim SA, Layden JE, Akkina S, Tang I, Campara M, et al. The use of fosfomycin to treat urinary tract infections in kidney transplant recipients. Transplantation. 2013;96(3):e12–4.PubMedCrossRefGoogle Scholar
  70. 70.
    Hariharan S. Recommendations for outpatient monitoring of kidney transplant recipients. Am J Kidney Dis. 2006;47(4 Suppl 2):S22–36.PubMedCrossRefGoogle Scholar
  71. 71.
    Golebiewska JE, Debska-Slizien A, Rutkowski B. Treated asymptomatic bacteriuria during first year after renal transplantation. Transpl Infect Dis. 2014;16(4):605–15.PubMedCrossRefGoogle Scholar
  72. 72.
    Green H, Rahamimov R, Goldberg E, Leibovici L, Gafter U, Bishara J, et al. Consequences of treated versus untreated asymptomatic bacteriuria in the first year following kidney transplantation: retrospective observational study. Eur J Clin Microbiol Infect Dis. 2013;32(1):127–31.PubMedCrossRefGoogle Scholar
  73. 73.
    Dupont PJ, Psimenou E, Lord R, Buscombe JR, Hilson AJ, Sweny P. Late recurrent urinary tract infections may produce renal allograft scarring even in the absence of symptoms or vesicoureteric reflux. Transplantation. 2007;84(3):351–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Bodro M, Sanclemente G, Lipperheide I, Allali M, Marco F, Bosch J, et al. Impact of antibiotic resistance on the development of recurrent and relapsing symptomatic urinary tract infection in kidney recipients. Am J Transplant. 2015;15(4):1021–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Safdar N, Slattery WR, Knasinski V, Gangnon RE, Li Z, Pirsch JD, et al. Predictors and outcomes of candiduria in renal transplant recipients. Clin Infect Dis. 2005;40(10):1413–21.PubMedCrossRefGoogle Scholar
  76. 76.
    Veroux M, Corona D, Giuffrida G, Gagliano M, Tallarita T, Giaquinta A, et al. Acute renal failure due to ureteral obstruction in a kidney transplant recipient with Candida albicans contamination of preservation fluid. Transpl Infect Dis. 2009;11(3):266–8.PubMedCrossRefGoogle Scholar
  77. 77.
    Walzer Y, Bear RA. Ureteral obstruction of renal transplant due to ureteral candidiasis. Urology. 1983;21(3):295–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Kamel G, Stephan A, Barbari A, Kilani H, Karam A, Zeineh S, et al. Obstructive anuria due to fungal bezoars in a renal graft recipient. Transplant Proc. 2003;35(7):2692–3.PubMedCrossRefGoogle Scholar
  79. 79.
    Albano L, Bretagne S, Mamzer-Bruneel MF, Kacso I, Desnos-Ollivier M, Guerrini P, et al. Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France. Clin Infect Dis. 2009;48(2):194–202.PubMedCrossRefGoogle Scholar
  80. 80.
    Mai H, Champion L, Ouali N, Hertig A, Peraldi MN, Glotz D, et al. Candida albicans arteritis transmitted by conservative liquid after renal transplantation: a report of four cases and review of the literature. Transplantation. 2006;82(9):1163–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Laouad I, Buchler M, Noel C, Sadek T, Maazouz H, Westeel PF, et al. Renal artery aneurysm secondary to Candida albicans in four kidney allograft recipients. Transplant Proc. 2005;37(6):2834–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Debska-Slizien A, Chrobak L, Bzoma B, Perkowska A, Zadrozny D, Chamienia A, et al. Candida arteritis in kidney transplant recipients: case report and review of the literature. Transpl Infect Dis. 2015;17(3):449–55.PubMedCrossRefGoogle Scholar
  83. 83.
    Matignon M, Botterel F, Audard V, Dunogue B, Dahan K, Lang P, et al. Outcome of renal transplantation in eight patients with Candida sp. contamination of preservation fluid. Am J Transplant. 2008;8(3):697–700.PubMedCrossRefGoogle Scholar
  84. 84.
    Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333–60.PubMedCrossRefGoogle Scholar
  85. 85.
    Razonable RR, Humar A, Practice ASTIDCo. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:93–106.Google Scholar
  86. 86.
    Reischig T, Jindra P, Svecova M, Kormunda S, Opatrny Jr K, Treska V. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol. 2006;36(2):146–51.PubMedCrossRefGoogle Scholar
  87. 87.
    Reischig T, Jindra P, Mares J, Cechura M, Svecova M, Hes O, et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation. 2005;79(3):317–24.PubMedCrossRefGoogle Scholar
  88. 88.
    Sola R, Diaz JM, Guirado L, Ravella N, Vila L, Sainz Z, et al. Significance of cytomegalovirus infection in renal transplantation. Transplant Proc. 2003;35(5):1753–5.PubMedCrossRefGoogle Scholar
  89. 89.
    Dickenmann MJ, Cathomas G, Steiger J, Mihatsch MJ, Thiel G, Tamm M. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation. 2001;71(6):764–7.PubMedCrossRefGoogle Scholar
  90. 90.
    Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 2008;8(5):975–83.PubMedCrossRefGoogle Scholar
  91. 91.
    Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10(5):1228–37.PubMedCrossRefGoogle Scholar
  92. 92.
    Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010;90(12):1427–31.PubMedCrossRefGoogle Scholar
  93. 93.
    Humar A, Paya C, Pescovitz MD, Dominguez E, Washburn K, Blumberg E, et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant. 2004;4(4):644–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Lisboa LF, Preiksaitis JK, Humar A, Kumar D. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation. 2011;92(9):1063–8.PubMedGoogle Scholar
  95. 95.
    Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56(6):817–24.PubMedCrossRefGoogle Scholar
  96. 96.
    Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008;8(1):69–77.PubMedGoogle Scholar
  97. 97.
    Pavlopoulou ID, Syriopoulou VP, Chelioti H, Daikos GL, Stamatiades D, Kostakis A, et al. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Clin Microbiol Infect. 2005;11(9):736–43.PubMedCrossRefGoogle Scholar
  98. 98.
    Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999;340(19):1462–70.PubMedCrossRefGoogle Scholar
  99. 99.
    Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7(9):2106–13.PubMedCrossRefGoogle Scholar
  100. 100.
    Asberg A, Humar A, Jardine AG, Rollag H, Pescovitz MD, Mouas H, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009;9(5):1205–13.PubMedCrossRefGoogle Scholar
  101. 101.
    Lautenschlager I, Jahnukainen T, Kardas P, Lohi J, Auvinen E, Mannonen L, et al. A case of primary JC polyomavirus infection-associated nephropathy. Am J Transplant. 2014;14(12):2887–92.PubMedCrossRefGoogle Scholar
  102. 102.
    Ginevri F, De Santis R, Comoli P, Pastorino N, Rossi C, Botti G, et al. Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation. 2003;75(8):1266–70.PubMedCrossRefGoogle Scholar
  103. 103.
    Awadalla Y, Randhawa P, Ruppert K, Zeevi A, Duquesnoy RJ. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant. 2004;4(10):1691–6.PubMedCrossRefGoogle Scholar
  104. 104.
    Khamash HA, Wadei HM, Mahale AS, Larson TS, Stegall MD, Cosio FG, et al. Polyomavirus-associated nephropathy risk in kidney transplants: the influence of recipient age and donor gender. Kidney Int. 2007;71(12):1302–9.PubMedCrossRefGoogle Scholar
  105. 105.
    Rocha PN, Plumb TJ, Miller SE, Howell DN, Smith SR. Risk factors for BK polyomavirus nephritis in renal allograft recipients. Clin Transpl. 2004;18(4):456–62.CrossRefGoogle Scholar
  106. 106.
    Smith JM, McDonald RA, Finn LS, Healey PJ, Davis CL, Limaye AP. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant. 2004;4(12):2109–17.PubMedCrossRefGoogle Scholar
  107. 107.
    Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, Cohen EP. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int. 2005;68(4):1834–9.PubMedCrossRefGoogle Scholar
  108. 108.
    Sharif A, Alachkar N, Bagnasco S, Geetha D, Gupta G, Womer K, et al. Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol. 2012;7(8):1320–7.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Hirsch HH, Vincenti F, Friman S, Tuncer M, Citterio F, Wiecek A, et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant. 2013;13(1):136–45.PubMedCrossRefGoogle Scholar
  110. 110.
    Lamoth F, Pascual M, Erard V, Venetz JP, Nseir G, Meylan P. Low-dose cidofovir for the treatment of polyomavirus-associated nephropathy: two case reports and review of the literature. Antivir Ther. 2008;13(8):1001–9.PubMedGoogle Scholar
  111. 111.
    Papanicolaou GA, Lee YJ, Young JW, Seshan SV, Boruchov AM, Chittick G, et al. Brincidofovir for polyomavirus-associated nephropathy after allogeneic hematopoietic stem cell transplantation. Am J Kidney Dis. 2015;65(5):780–4.PubMedCrossRefGoogle Scholar
  112. 112.
    Josephson MA, Gillen D, Javaid B, Kadambi P, Meehan S, Foster P, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation. 2006;81(5):704–10.PubMedCrossRefGoogle Scholar
  113. 113.
    Krisl JC, Taber DJ, Pilch N, Chavin K, Bratton C, Thomas B, et al. Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection. Clin J Am Soc Nephrol. 2012;7(6):1003–9.PubMedCrossRefGoogle Scholar
  114. 114.
    Leung AY, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL, et al. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40(4):528–37.PubMedCrossRefGoogle Scholar
  115. 115.
    Knoll GA, Humar A, Fergusson D, Johnston O, House AA, Kim SJ, et al. Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. JAMA. 2014;312(20):2106–14.PubMedCrossRefGoogle Scholar
  116. 116.
    Lee BT, Gabardi S, Grafals M, Hofmann RM, Akalin E, Aljanabi A, et al. Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial. Clin J Am Soc Nephrol. 2014;9(3):583–9.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Ramos E, Vincenti F, Lu WX, Shapiro R, Trofe J, Stratta RJ, et al. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation. 2004;77(1):131–3.PubMedCrossRefGoogle Scholar
  118. 118.
    Hirsch HH, Randhawa P, Practice ASTIDCo. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:179–88.Google Scholar
  119. 119.
    Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev. 2008;21(4):704–15.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Watcharananan SP, Avery R, Ingsathit A, Malathum K, Chantratita W, Mavichak V, et al. Adenovirus disease after kidney transplantation: course of infection and outcome in relation to blood viral load and immune recovery. Am J Transplant. 2011;11(6):1308–14.PubMedCrossRefGoogle Scholar
  121. 121.
    Saquib R, Melton LB, Chandrakantan A, Rice KM, Spak CW, Saad RD, et al. Disseminated adenovirus infection in renal transplant recipients: the role of cidofovir and intravenous immunoglobulin. Transpl Infect Dis. 2010;12(1):77–83.PubMedCrossRefGoogle Scholar
  122. 122.
    Hofland CA, Eron LJ, Washecka RM. Hemorrhagic adenovirus cystitis after renal transplantation. Transplant Proc. 2004;36(10):3025–7.PubMedCrossRefGoogle Scholar
  123. 123.
    Humar A, Kumar D, Mazzulli T, Razonable RR, Moussa G, Paya CV, et al. A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am J Transplant. 2005;5(10):2555–9.PubMedCrossRefGoogle Scholar
  124. 124.
    Waldman M, Kopp JB. Parvovirus-B19-associated complications in renal transplant recipients. Nat Clin Pract Nephrol. 2007;3(10):540–50.PubMedCrossRefGoogle Scholar
  125. 125.
    Gosset C, Viglietti D, Hue K, Antoine C, Glotz D, Pillebout E. How many times can parvovirus B19-related anemia recur in solid organ transplant recipients? Transpl Infect Dis. 2012;14(5):E64–70.PubMedCrossRefGoogle Scholar
  126. 126.
    Porignaux R, Vuiblet V, Barbe C, Nguyen Y, Lavaud S, Toupance O, et al. Frequent occurrence of parvovirus B19 DNAemia in the first year after kidney transplantation. J Med Virol. 2013;85(6):1115–21.PubMedCrossRefGoogle Scholar
  127. 127.
    Egbuna O, Zand MS, Arbini A, Menegus M, Taylor J. A cluster of parvovirus B19 infections in renal transplant recipients: a prospective case series and review of the literature. Am J Transplant. 2006;6(1):225–31.PubMedCrossRefGoogle Scholar
  128. 128.
    Winston DJ, Vikram HR, Rabe IB, Dhillon G, Mulligan D, Hong JC, et al. Donor-derived West Nile virus infection in solid organ transplant recipients: report of four additional cases and review of clinical, diagnostic, and therapeutic features. Transplantation. 2014;97(9):881–9.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Inojosa WO, Scotton PG, Fuser R, Giobbia M, Paolin A, Maresca MC, et al. West Nile virus transmission through organ transplantation in north-eastern Italy: a case report and implications for pre-procurement screening. Infection. 2012;40(5):557–62.PubMedCrossRefGoogle Scholar
  130. 130.
    Rabe IB, Schwartz BS, Farnon EC, Josephson SA, Webber AB, Roberts JP, et al. Fatal transplant-associated West Nile virus encephalitis and public health investigation-California, 2010. Transplantation. 2013;96(5):463–8.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Centers for Disease C, Prevention. West Nile virus transmission via organ transplantation and blood transfusion—Louisiana, 2008. Morb Mortal Wkly Rep. 2009;58(45):1263–7.Google Scholar
  132. 132.
    Iwamoto M, Jernigan DB, Guasch A, Trepka MJ, Blackmore CG, Hellinger WC, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med. 2003;348(22):2196–203.PubMedCrossRefGoogle Scholar
  133. 133.
    Kumar D, Prasad GV, Zaltzman J, Levy GA, Humar A. Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation. 2004;77(3):399–402.PubMedCrossRefGoogle Scholar
  134. 134.
    Ravindra KV, Freifeld AG, Kalil AC, Mercer DF, Grant WJ, Botha JF, et al. West Nile virus-associated encephalitis in recipients of renal and pancreas transplants: case series and literature review. Clin Infect Dis. 2004;38(9):1257–60.PubMedCrossRefGoogle Scholar
  135. 135.
    Wadei H, Alangaden GJ, Sillix DH, El-Amm JM, Gruber SA, West MS, et al. West Nile virus encephalitis: an emerging disease in renal transplant recipients. Clin Transpl. 2004;18(6):753–8.CrossRefGoogle Scholar
  136. 136.
    Kleinschmidt-DeMasters BK, Marder BA, Levi ME, Laird SP, McNutt JT, Escott EJ, et al. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch Neurol. 2004;61(8):1210–20.PubMedCrossRefGoogle Scholar
  137. 137.
    Kumar D, Drebot MA, Wong SJ, Lim G, Artsob H, Buck P, et al. A seroprevalence study of West Nile virus infection in solid organ transplant recipients. Am J Transplant. 2004;4(11):1883–8.PubMedCrossRefGoogle Scholar
  138. 138.
    Morelli MC, Sambri V, Grazi GL, Gaibani P, Pierro A, Cescon M, et al. Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. Clin Infect Dis. 2010;51(4):e34–7.PubMedCrossRefGoogle Scholar
  139. 139.
    Rhee C, Eaton EF, Concepcion W, Blackburn BG. West Nile virus encephalitis acquired via liver transplantation and clinical response to intravenous immunoglobulin: case report and review of the literature. Transpl Infect Dis. 2011;13(3):312–7.PubMedCrossRefGoogle Scholar
  140. 140.
    Gea-Banacloche J, Johnson RT, Bagic A, Butman JA, Murray PR, Agrawal AG. West Nile virus: pathogenesis and therapeutic options. Ann Intern Med. 2004;140(7):545–53.PubMedCrossRefGoogle Scholar
  141. 141.
    Haley M, Retter AS, Fowler D, Gea-Banacloche J, O'Grady NP. The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis. Clin Infect Dis. 2003;37(6):e88–90.PubMedCrossRefGoogle Scholar
  142. 142.
    Post FA, Holt SG. Recent developments in HIV and the kidney. Curr Opin Infect Dis. 2009;22(1):43–8.PubMedCrossRefGoogle Scholar
  143. 143.
    Rosenberg AZ, Naicker S, Winkler CA, Kopp JB. HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nat Rev Nephrol. 2015;11(3):150–60.PubMedCrossRefGoogle Scholar
  144. 144.
    Locke JE, Mehta S, Reed RD, MacLennan P, Massie A, Nellore A, et al. A national study of outcomes among HIV-infected kidney transplant recipients. J Am Soc Nephrol. 2015;26(9):2222–9.Google Scholar
  145. 145.
    Xia Y, Friedmann P, Yaffe H, Phair J, Gupta A, Kayler LK. Effect of HCV, HIV and coinfection in kidney transplant recipients: mate kidney analyses. Am J Transplant. 2014;14(9):2037–47.PubMedCrossRefGoogle Scholar
  146. 146.
    Locke JE, Reed RD, Mehta SG, Durand C, Mannon RB, MacLennan P, et al. Center-level experience and kidney transplant outcomes in HIV-infected recipients. Am J Transplant. 2015;15(8):2096–104.PubMedCrossRefGoogle Scholar
  147. 147.
    Locke JE, James NT, Mannon RB, Mehta SG, Pappas PG, Baddley JW, Desai NM, Montgomery RA, Segev DL. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation. 2014 Feb 27;97(4):446–50.Google Scholar
  148. 148.
    Gruber SA, Doshi MD, Cincotta E, Brown KL, Singh A, Morawski K, et al. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation. 2008;86(2):269–74.PubMedCrossRefGoogle Scholar
  149. 149.
    Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004–14.PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    Blumberg EA, Rogers CC, Practice ASTIDCo. Human immunodeficiency virus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:169–78.PubMedCrossRefGoogle Scholar
  151. 151.
    Muller E, Kahn D, Mendelson M. Renal transplantation between HIV-positive donors and recipients. N Engl J Med. 2010;362(24):2336–7.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Muller E. Transplantation in resource-limited setting: using HIV-positive donors for HIV-positive patients. Clin Nephrol. 2015;83(7 Suppl 1):39–41.PubMedCrossRefGoogle Scholar
  153. 153.
    Muller E, Barday Z, Mendelson M, Kahn D. HIV-positive-to-HIV-positive kidney transplantation--results at 3 to 5 years. N Engl J Med. 2015;372(7):613–20.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Malani PN. New law allows organ transplants from deceased HIV-infected donors to HIV-infected recipients. JAMA. 2013;310(23):2492–3.PubMedCrossRefGoogle Scholar
  155. 155.
    Khamash HA, Gaston RS. Transplant tourism: a modern iteration of an ancient problem. Curr Opin Organ Transplant. 2008;13(4):395–9.PubMedCrossRefGoogle Scholar
  156. 156.
    Sajjad I, Baines LS, Patel P, Salifu MO, Jindal RM. Commercialization of kidney transplants: a systematic review of outcomes in recipients and donors. Am J Nephrol. 2008;28(5):744–54.PubMedCrossRefGoogle Scholar
  157. 157.
    Canales MT, Kasiske BL, Rosenberg ME. Transplant tourism: outcomes of United States residents who undergo kidney transplantation overseas. Transplantation. 2006;82(12):1658–61.PubMedCrossRefGoogle Scholar
  158. 158.
    Prasad GV, Shukla A, Huang M, D’A Honey RJ, Zaltzman JS. Outcomes of commercial renal transplantation: a Canadian experience. Transplantation. 2006;82(9):1130–5.PubMedCrossRefGoogle Scholar
  159. 159.
    Geddes CC, Henderson A, Mackenzie P, Rodger SC. Outcome of patients from the west of Scotland traveling to Pakistan for living donor kidney transplants. Transplantation. 2008;86(8):1143–5.PubMedCrossRefGoogle Scholar
  160. 160.
    The Declaration of Istanbul on Organ Trafficking and Transplant Tourism. Istanbul Summit April 30-May 2, 2008. Nephrol Dial Transplant. 2008;23(11):3375–80.Google Scholar
  161. 161.
    Hurst FP, Lee JJ, Jindal RM, Agodoa LY, Abbott KC. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol. 2011;6(5):1192–7.PubMedPubMedCentralCrossRefGoogle Scholar
  162. 162.
    Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis. 2003;187(10):1639–45.PubMedCrossRefGoogle Scholar
  163. 163.
    Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients--three year follow-up of a randomized trial. Am J Transplant. 2007;7(3):633–8.PubMedCrossRefGoogle Scholar
  164. 164.
    Kumar D, Gourishankar S, Mueller T, Cockfield S, Weinkauf J, Vethanayagam D, et al. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl Infect Dis. 2009;11(2):167–70.PubMedCrossRefGoogle Scholar
  165. 165.
    Batiuk TD, Bodziak KA, Goldman M. Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers. Clin Transpl. 2002;16(1):1–8.CrossRefGoogle Scholar
  166. 166.
    Radisic M, Lattes R, Chapman JF, del Carmen RM, Guardia O, Seu F, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis. 2003;5(2):84–93.PubMedCrossRefGoogle Scholar
  167. 167.
    Chapman JR, Marriott DJ, Chen SC, MacDonald PS. Post-transplant Pneumocystis jirovecii pneumonia—a re-emerged public health problem? Kidney Int. 2013;84(2):240–3.PubMedCrossRefGoogle Scholar
  168. 168.
    Rostved AA, Sassi M, Kurtzhals JA, Sorensen SS, Rasmussen A, Ross C, et al. Outbreak of pneumocystis pneumonia in renal and liver transplant patients caused by genotypically distinct strains of Pneumocystis jirovecii. Transplantation. 2013;96(9):834–42.PubMedCrossRefGoogle Scholar
  169. 169.
    Le Gal S, Damiani C, Rouille A, Grall A, Treguer L, Virmaux M, et al. A cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin Infect Dis. 2012;54(7):e62–71.PubMedCrossRefGoogle Scholar
  170. 170.
    Gabardi S, Millen P, Hurwitz S, Martin S, Roberts K, Chandraker A. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation. Clin Transpl. 2012;26(3):E184–90.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  1. 1.Multi-Organ Transplant ProgramUniversity Health NetworkTorontoCanada

Personalised recommendations